## Highlights of This Issue

### SPECIAL FEATURES

#### CCR 20th Anniversary Commentary

- **939** CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
  Beverly A. Teicher and Kenneth C. Anderson

- **942** CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
  Clint T. Allen, Barbara Conley, John B. Sunwoo, and Carter Van Wae

#### CCR Translations

- **944** Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
  Roxana S. Dronca and Haidong Dong

- **947** Moving from Evaluation to Value in Cancer Care
  Richard L. Schilsky

#### CCR Perspectives in Drug Approval

- **950** FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
  Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F. Zirkelbach, Liang Zhao, Julie Bullock, Nitin Mehrotra, Pedro Del Valle, Haleh Saber, Christopher Sheth, Brenda Gehrke, Robert Justice, Ann Farrell, and Richard Pazdur

#### Molecular Pathways

- **955** Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
  Rebecca A. Prieve, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood

- **962** Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis
  Hae-Yun Jung, Laurent Fattet, and Jing Yang

### Reviews

- **969** Zebrafish: A New Companion for Translational Research in Oncology
  Jorge Barriuso, Raghavendr Nagaraju, and Adam Hurstone

- **976** Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
  Valsamo K. Anagnostou and Julie R. Brahmer

### CANCER THERAPY: CLINICAL

- **985** A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

- **995** CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb⁺ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
  Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gamlich, Maryann Gallagher, Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Domschek, Kerihi Gogineni, Mark Rosen, Kevin Fox, and Peter O’Dwyer

- **1002** Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

- **1010** Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions
1127  Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, and Karl Erik Hellstrom
See related commentary, p. 944

1139  Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing’s Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Min H. Kang, Jing Wang, Monish R. Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, and C. Patrick Reynolds

1151  Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

1161  Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Sevim Dalva-Aydemir, Richa Baijaj, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changrong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, and Mala Shanmugam

1172  Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy

1183  Integrinβ6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma
Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao, Ruliang Fang, Zheng-huan Niu, Song Liu, Ben Wang, Qi Sun, Weibo Niu, Enyu Liu, Bayong Wang, and Jun Niu

1196  Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Muneeer, Stephan Beck, and John D. Kelly

1207  A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Kristine Kleivi Sahlberg, Giulia Bottai, Bjorn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Berresen-Dale, and Libero Santarpia

1215  Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphael Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svreck, Jérôme Cros, Armelle Bardier-Dupas, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Trou, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, and Jean-Luc Van Laethem

1225  Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinfei Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lutao Du, and Chuanxin Wang
ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.